Potential metal impurities in active pharmaceutical substances and finished medicinal products – A market surveillance study

• Active pharmaceutical substances and finished medicinal products have been screened for metal impurities.
• Different atomic spectrometric methods were used.
• Validation results using synthetic matrix and real tablets were presented.
• No noteworthy contamination with metal reagents could be measured.

A market surveillance study has been established by using different atomic spectrometric methods for the determination of selected elemental impurities of particular interest, to gain an overview about the quality of presently marketed drug products and their bulk drug substances. The limit tests were carried out with respect to the existing EMA guideline on the specification limits for residuals of metal catalysts or metal reagents. Also attention was given to the future implementation of two new chapters of the United States Pharmacopoeia (USP) stating limit concentrations of elemental impurities. The methods used for determination of metal residues were inductively coupled plasma-mass spectrometry (ICP-MS), inductively coupled plasma-optical emission spectrometry (ICP-OES), and atomic absorption spectrometry technologies (GFAAS, CVAAS, HGAAS). This article presents the development and validation of the methods used for the determination of 21 selected metals in 113 samples from drug products and their active pharmaceutical ingredients.

Figure optionsDownload high-quality image (146 K)Download as PowerPoint slide